These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

412 related articles for article (PubMed ID: 29429782)

  • 1. Long-Term Treatment of Niemann-Pick Type C1 Disease With Intrathecal 2-Hydroxypropyl-β-Cyclodextrin.
    Berry-Kravis E; Chin J; Hoffmann A; Winston A; Stoner R; LaGorio L; Friedmann K; Hernandez M; Ory DS; Porter FD; O'Keefe JA
    Pediatr Neurol; 2018 Mar; 80():24-34. PubMed ID: 29429782
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intrathecal 2-hydroxypropyl-β-cyclodextrin decreases neurological disease progression in Niemann-Pick disease, type C1: a non-randomised, open-label, phase 1-2 trial.
    Ory DS; Ottinger EA; Farhat NY; King KA; Jiang X; Weissfeld L; Berry-Kravis E; Davidson CD; Bianconi S; Keener LA; Rao R; Soldatos A; Sidhu R; Walters KA; Xu X; Thurm A; Solomon B; Pavan WJ; Machielse BN; Kao M; Silber SA; McKew JC; Brewer CC; Vite CH; Walkley SU; Austin CP; Porter FD
    Lancet; 2017 Oct; 390(10104):1758-1768. PubMed ID: 28803710
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Expanded access with intravenous hydroxypropyl-β-cyclodextrin to treat children and young adults with Niemann-Pick disease type C1: a case report analysis.
    Hastings C; Vieira C; Liu B; Bascon C; Gao C; Wang RY; Casey A; Hrynkow S
    Orphanet J Rare Dis; 2019 Oct; 14(1):228. PubMed ID: 31639011
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intrathecal 2-hydroxypropyl-beta-cyclodextrin in a single patient with Niemann-Pick C1.
    Maarup TJ; Chen AH; Porter FD; Farhat NY; Ory DS; Sidhu R; Jiang X; Dickson PI
    Mol Genet Metab; 2015; 116(1-2):75-9. PubMed ID: 26189084
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anesthetic management of pediatric patients with Niemann-Pick disease type C for intrathecal 2-hydroxypropyl-β-cyclodextrin injection.
    Ulloa ML; Froyshteter AB; Kret LN; Chang DP; Sarah GE; McCarthy RJ; Barnes SD; Berry-Kravis EM
    Paediatr Anaesth; 2020 Jul; 30(7):766-772. PubMed ID: 32349180
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-Term Neuropsychological Outcomes from an Open-Label Phase I/IIa Trial of 2-Hydroxypropyl-β-Cyclodextrins (VTS-270) in Niemann-Pick Disease, Type C1.
    Farmer CA; Thurm A; Farhat N; Bianconi S; Keener LA; Porter FD
    CNS Drugs; 2019 Jul; 33(7):677-683. PubMed ID: 31187454
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Low Risk Profile of Long-Term Repeated Lumbar Puncture for Intrathecal Delivery of 2-Hydroxypropyl-Beta-Cyclodextrin in Patients With Niemann-Pick Type C.
    Albert OK; Friedmann K; Jaeger R; Berry-Kravis E
    Pediatr Neurol; 2023 Jul; 144():99-103. PubMed ID: 37201244
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Polyrotaxane-based systemic delivery of β-cyclodextrins for potentiating therapeutic efficacy in a mouse model of Niemann-Pick type C disease.
    Tamura A; Yui N
    J Control Release; 2018 Jan; 269():148-158. PubMed ID: 29138063
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term efficacy of intrathecal cyclodextrin in patients with Niemann-Pick disease type C.
    Matsuo M; Sakakibara T; Sakiyama Y; So T; Kosuga M; Kakiuchi T; Ichinose F; Nakamura T; Ishitsuka Y; Irie T
    Brain Dev; 2024 May; 46(5):207-212. PubMed ID: 38448301
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chronic cyclodextrin treatment of murine Niemann-Pick C disease ameliorates neuronal cholesterol and glycosphingolipid storage and disease progression.
    Davidson CD; Ali NF; Micsenyi MC; Stephney G; Renault S; Dobrenis K; Ory DS; Vanier MT; Walkley SU
    PLoS One; 2009 Sep; 4(9):e6951. PubMed ID: 19750228
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differential mode of cholesterol inclusion with 2-hydroxypropyl-cyclodextrins increases safety margin in treatment of Niemann-Pick disease type C.
    Yamada Y; Ishitsuka Y; Kondo Y; Nakahara S; Nishiyama A; Takeo T; Nakagata N; Motoyama K; Higashi T; Arima H; Kamei S; Shuto T; Kai H; Hayashino Y; Sugita M; Kikuchi T; Hirata F; Miwa T; Takeda H; Orita Y; Seki T; Ohta T; Kurauchi Y; Katsuki H; Matsuo M; Higaki K; Ohno K; Matsumoto S; Era T; Irie T
    Br J Pharmacol; 2021 Jul; 178(13):2727-2746. PubMed ID: 33782944
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differential Effects of 2-Hydroxypropyl-Cyclodextrins on Lipid Accumulation in
    Hoque S; Kondo Y; Sakata N; Yamada Y; Fukaura M; Higashi T; Motoyama K; Arima H; Higaki K; Hayashi A; Komiya T; Ishitsuka Y; Irie T
    Int J Mol Sci; 2020 Jan; 21(3):. PubMed ID: 32019132
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 2-Hydroxypropyl-β-cyclodextrins and the Blood-Brain Barrier: Considerations for Niemann-Pick Disease Type C1.
    Calias P
    Curr Pharm Des; 2017; 23(40):6231-6238. PubMed ID: 29065825
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hydroxypropyl-beta and -gamma cyclodextrins rescue cholesterol accumulation in Niemann-Pick C1 mutant cell via lysosome-associated membrane protein 1.
    Singhal A; Szente L; Hildreth JEK; Song B
    Cell Death Dis; 2018 Oct; 9(10):1019. PubMed ID: 30282967
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Endocytosis of beta-cyclodextrins is responsible for cholesterol reduction in Niemann-Pick type C mutant cells.
    Rosenbaum AI; Zhang G; Warren JD; Maxfield FR
    Proc Natl Acad Sci U S A; 2010 Mar; 107(12):5477-82. PubMed ID: 20212119
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In Vitro and In Vivo Evaluation of 6-O-α-Maltosyl-β-Cyclodextrin as a Potential Therapeutic Agent Against Niemann-Pick Disease Type C.
    Yasmin N; Ishitsuka Y; Fukaura M; Yamada Y; Nakahara S; Ishii A; Kondo Y; Takeo T; Nakagata N; Motoyama K; Higashi T; Okada Y; Nishikawa J; Ichikawa A; Iohara D; Hirayama F; Higaki K; Ohno K; Matsuo M; Irie T
    Int J Mol Sci; 2019 Mar; 20(5):. PubMed ID: 30845767
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Modeling Niemann-Pick disease type C1 in zebrafish: a robust platform for
    Tseng WC; Loeb HE; Pei W; Tsai-Morris CH; Xu L; Cluzeau CV; Wassif CA; Feldman B; Burgess SM; Pavan WJ; Porter FD
    Dis Model Mech; 2018 Aug; 11(9):. PubMed ID: 30135069
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term administration of intravenous Trappsol® Cyclo™ (HP-β-CD) results in clinical benefits and stabilization or slowing of disease progression in patients with Niemann-Pick disease type C1: Results of an international 48-week Phase I/II trial.
    Sharma R; Hastings C; Staretz-Chacham O; Raiman J; Paucar M; Spiegel R; Murray B; Hurst B; Liu B; Kjems L; Hrynkow S
    Mol Genet Metab Rep; 2023 Sep; 36():100988. PubMed ID: 37670901
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intravenous 2-hydroxypropyl-β-cyclodextrin (Trappsol® Cyclo™) demonstrates biological activity and impacts cholesterol metabolism in the central nervous system and peripheral tissues in adult subjects with Niemann-Pick Disease Type C1: Results of a phase 1 trial.
    Hastings C; Liu B; Hurst B; Cox GF; Hrynkow S
    Mol Genet Metab; 2022 Dec; 137(4):309-319. PubMed ID: 36279795
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neurofilament light chain in cerebrospinal fluid as a novel biomarker in evaluating both clinical severity and therapeutic response in Niemann-Pick disease type C1.
    Agrawal N; Farhat NY; Sinaii N; Do AD; Xiao C; Berry-Kravis E; Bianconi S; Masvekar R; Bielekova B; Solomon B; Porter FD
    Genet Med; 2023 Mar; 25(3):100349. PubMed ID: 36470574
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.